Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Sonoma Pharmaceuticals, Inc. is not a good value stock. Sonoma Pharmaceuticals, Inc. has good growth characteristics. Sonoma Pharmaceuticals, Inc. is not very popular among insiders. Sonoma Pharmaceuticals, Inc. is a mediocre stock to choose.

Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for c...

News

Sonoma Pharmaceuticals, EMC Pharma enter co-marketing collaboration

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line

Accesswire BOULDER, CO / ACCESSWIRE / September 11, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn(R) technology based stabilized...\n more…

Sonoma Pharmaceuticals trading halted, news pending

Sonoma Pharmaceuticals to implement a reverse stock split

SeekingAlpha.com: All News no summary\n more…

Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock

Accesswire BOULDER, CO / ACCESSWIRE / August 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn(R) technology based stabilized...\n more…

Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower

Simply Wall St Sonoma Pharmaceuticals, Inc. ( NASDAQ:SNOA ) shares have retraced a considerable 33% in the last month, reversing a...\n more…